



1645/DFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-764-B (400.216US))

In application of:

Chowrira, et al.

Serial No.: 10/567,888

Filed: December 15, 2006

For: RNA interference mediated inhibition of Xiap Gene
Expression using Short Interfering Nucleic Acid
(siNA)

Examiner: TBA

Group Art Unit: 1645

Conf. No. 2856

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Application Processing Division
Customer Correction Branch

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Request for Corrected Filing Receipt;
 - b) Return Postcard;
2. It is believed no fee is due at this time.
3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 26, 2007.

Respectfully submitted,

Date: March 26, 2007

/Lisa M.W. Hillman/
Lisa M.W. Hillman, Ph.D
Registration No. 43,673



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-764-B (400.216US))

In application of:)
)
 Chowrira, et al.)
)
 Serial No.: 10/567,888) Examiner: TBA
)
 Filed: December 15, 2006) Group Art Unit: 1645
)
 Conf. No. 2856
 For: RNA interference mediated inhibition of Xiap Gene)
 Expression using Short Interfering Nucleic Acid)
 (siNA))

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Application Processing Division
Customer Correction Branch

Dear Sir:

1. Attached is a copy of the official filing receipt received from the PTO in the above-referenced application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is incorrectly entered.

Error In

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/25589 08/06/2004
Which claims the benefit of 60/493,561 08/08/2003
And claims the benefit of 60/543,480 02/10/2004
And is a CIP of 10/826,966 04/16/2004
Which is a CIP of 10/757,803 01/14/2004
Which is a CIP of 10/720,448 11/24/2003 ABN
Which is a CIP of 10/693,059 10/23/2003 ABN
Which is a CIP of 10/444,853 05/23/2003
And is a CIP of 10/652,791 08/29/2003

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
(312)913-0001

Copied from 11567888 on 04/23/2007

Which is a CON of 10/422,704 04/24/2003 ABN
Which is a CON of 10/417,012 04/16/2003 ABN
And said 10/826,966 04/16/2004
Is a CIP of PCT/US03/05346 02/20/2003
And is a CIP of PCT/US03/05028 02/20/2003
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/358,580 02/20/2002
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/358,580 02/20/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/363,124 03/11/2002
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/363,124 03/11/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/386,782 06/06/2002
And said PCT/US03/05028 02/20/2003
Is a CIP of 60/386,782 06/06/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/406,784 08/29/2002
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/406,784 08/29/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/408,378 09/05/2002
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/408,378 09/05/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/409,293 09/09/2002
And said 10/826,966 04/16/2004
Is a CIP of 10/780,447 02/13/2004
Which is a CIP of 10/427,167 04/30/2003
And is a CIP of PCT/US02/15876 05/17/2002
Which claims benefit of 60/292,217 05/18/2001
And claims benefit of 60/362,016 03/06/2002
And claims benefit of 60/306,883 07/20/2001
And claims benefit of 60/311,865 08/13/2001
And said 10/826,996 04/16/2004
Is a CIP of 10/727,780 12/03/2003
And claims the benefit of 60/543,480 02/10/2004

Correct Data

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/25589 08/06/2004
Which claims the benefit of 60/493,561 08/08/2003
This application is a CIP of PCT/US04/16390 05/24/2004
And is a CIP of 10/826,966 04/16/2004
Which is a CIP of 10/757,803 01/14/2004
Which is a CIP of 10/720,448 11/24/2003 ABN
Which is a CIP of 10/693,059 10/23/2003 ABN
Which is a CIP of 10/444,853 05/23/2003
Is a CIP of PCT/US03/05346 02/20/2003
And is a CIP of PCT/US03/05028 02/20/2003
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/358,580 02/20/2002
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/358,580 02/20/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/363,124 03/11/2002
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/363,124 03/11/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/386,782 06/06/2002
And said PCT/US03/05028 02/20/2003
Is a CIP of 60/386,782 06/06/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/406,784 08/29/2002
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/406,784 08/29/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/408,378 09/05/2002
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/408,378 09/05/2002
And said PCT/US03/05346 02/20/2203
Claims benefit of 60/409,293 09/09/2002
And said PCT/US03/05028 02/20/2003
Claims the benefit of 60/409,293 09/09/2002
And said PCT/US03/05346 02/20/2003
Claims benefit of 60/440,129 01/15/2003
And said PCT/US03/05028 02/20/2003
Claims benefit of 60/440,129 01/15/2003
This application is a CIP of PCT/US04/13456 04/30/2004
Which is a continuation of 10/780,447 02/13/2004
Which is a CIP of 10/427,167 04/30/2003
And is a CIP of PCT/US02/15876 05/17/2002
Which claims benefit of 60/292,217 05/18/2001

And claims benefit of 60/362,016 03/06/2002
And claims benefit of **60/363,883** 07/20/2001
And claims benefit of 60/311,865 08/13/2001
This application is a CIP of 10/727,780 12/03/2003
This application claims the benefit of 60/543,480 02/10/2004

3. The correction is not due to any error by applicant and no fee is due.

Respectfully submitted,

Date: March 26, 2007

/Lisa M.W. Hillman/
Lisa M.W. Hillman, Ph.D
Registration No. 43,673



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/567,888	12/15/2006	1645	1115	03-764-B (400.216US)	25	35	1

CONFIRMATION NO. 2856

20306

MCDONNELL BOEHNEN HULBERT & BERGHOF, LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO, IL 60606

DOCKETED

JAN 23 2007

DUE DATE: IDS 5-7-06
BY: [Signature]

FILING RECEIPT



OC000000022007988

Date Mailed: 01/17/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Bharat M. Chowrira, San Francisco, CA; ✓
James McSwiggen, Broomfield, CO; ✓

Assignment For Published Patent Application

Sirna Therapeutics, Inc., Boulder, CO

Power of Attorney: The patent practitioners associated with Customer Number 20306.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/25589 08/06/2004 ✓
which claims benefit of 60/493,561 08/08/2003 ✓
~~and claims benefit of 60/543,480 02/10/2004~~ → This application is a CIP of PCT/US04/16390
and is a CIP of 10/826,966 04/16/2004 ✓
which is a CIP of 10/757,803 01/14/2004 ✓
which is a CIP of 10/720,448 11/24/2003 ABN ✓
which is a CIP of 10/693,059 10/23/2003 ABN ✓
which is a CIP of 10/444,853 05/23/2003 ✓
and is a CIP of 10/652,791 08/29/2003 ✓
which is a CON of 10/422,704 04/24/2003 ABN ✓
~~which is a CON of 10/417,012 04/16/2003 ABN~~
~~and said 10/826,966 04/16/2004~~
is a CIP of PCT/US03/05346 02/20/2003 ✓
and is a CIP of PCT/US03/05028 02/20/2003 ✓
and said PCT/US03/05346 02/20/2003 ✓
claims benefit of 60/358,580 02/20/2002 ✓
and said PCT/US03/05028 02/20/2003 ✓

→ This application is a CIP of PCT/US04/16390
OS 24.04

claims benefit of 60/358,580 02/20/2002 ✓
 and said PCT/US03/05346 02/20/2003 ✓
 claims benefit of 60/363,124 03/11/2002 ✓
 and said PCT/US03/05028 02/20/2003 ✓
 claims benefit of 60/363,124 03/11/2002 ✓
 and said PCT/US03/05346 02/20/2003 ✓
 claims benefit of 60/386,782 06/06/2002 ✓
 and said PCT/US03/05028 02/20/2003 ✓
 is a CIP of 60/386,782 06/06/2002 ✓
 and said PCT/US03/05346 02/20/2003 ✓
 claims benefit of 60/406,784 08/29/2002 ✓
 and said PCT/US03/05028 02/20/2003 ✓
 claims benefit of 60/406,784 08/29/2002 ✓
 and said PCT/US03/05346 02/20/2003 ✓
 claims benefit of 60/408,378 09/05/2002 ✓
 and said PCT/US03/05028 02/20/2003 ✓
 claims benefit of 60/408,378 09/05/2002 ✓
 and said PCT/US03/05346 02/20/2003 ✓
 claims benefit of 60/409,293 09/09/2002 ✓
 and said ~~10/826,966 04/10/2004~~ and said PCT/US03/05028 2/20/03
 is a CIP of ~~10/780,447 02/13/2004~~ Claims the benefit of 60/409,293 9/09/02
 which is a CIP of 10/427,160 04/30/2003 ✓
 and is a CIP of PCT/US02/15876 05/17/2002 ✓
 which claims benefit of 60/292,217 05/18/2001 ✓
 and claims benefit of 60/362,016 03/06/2002 ✓
 and claims benefit of ~~60/306,883 07/20/2001~~ 60/303,883 ✓
 and claims benefit of 60/311,865 08/13/2001 ✓
 and said ~~10/826,966 04/10/2004~~
 is a CIP of 10/727,780 12/03/2003 ✓
 and claims benefit of 60/543,480 02/10/2004 ✓

↓
 add said PCT/US03/05346 2/20/03
 claims the benefit of 60/440,129 1/15/03
 and said PCT/US03/05028 2/20/03
 claims the benefit of 60/440,129 1/15/03

This application is a CIP of PCT/US04/13456
 4.30.2004

which is a continuation of 10/780,447
 2.13.04

Foreign Applications

If Required, Foreign Filing License Granted: 01/16/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/567,888**

Projected Publication Date: 04/26/2007

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid ✓
 (sina)

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).